Net Cash Provided by (Used in) Operating Activities in USD of Taysha Gene Therapies, Inc. from Q3 2019 to Q1 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
Summary
Taysha Gene Therapies, Inc. quarterly/annual Net Cash Provided by (Used in) Operating Activities history and growth rate from Q3 2019 to Q1 2025.
  • Taysha Gene Therapies, Inc. Net Cash Provided by (Used in) Operating Activities for the quarter ending March 31, 2025 was -$22M, a 11.2% decline year-over-year.
  • Taysha Gene Therapies, Inc. annual Net Cash Provided by (Used in) Operating Activities for 2024 was -$81.2M, a 11.2% decline from 2023.
  • Taysha Gene Therapies, Inc. annual Net Cash Provided by (Used in) Operating Activities for 2023 was -$73M, a 17.4% increase from 2022.
  • Taysha Gene Therapies, Inc. annual Net Cash Provided by (Used in) Operating Activities for 2022 was -$88.4M, a 24.5% increase from 2021.
Net Cash Provided by (Used in) Operating Activities, Quarterly (USD)
Net Cash Provided by (Used in) Operating Activities, YoY Quarterly Growth (%)
Net Cash Provided by (Used in) Operating Activities, Annual (USD)
Net Cash Provided by (Used in) Operating Activities, YoY Annual Growth (%)

Taysha Gene Therapies, Inc. Quarterly Net Cash Provided by (Used in) Operating Activities (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2025 -$22M -$2.22M -11.2% Jan 1, 2025 Mar 31, 2025 10-Q 2025-05-15
Q1 2024 -$19.8M +$387K +1.92% Jan 1, 2024 Mar 31, 2024 10-Q 2025-05-15
Q1 2023 -$20.2M +$20.8M +50.7% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-14
Q1 2022 -$40.9M -$18.9M -85.8% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-11
Q1 2021 -$22M -$20.3M -1197% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-16
Q1 2020 -$1.7M Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-11
Q4 2019 $0 Sep 21, 2019 Dec 31, 2019 10-K 2021-03-03
Q3 2019 $0 Sep 21, 2019 Sep 30, 2019 10-Q 2020-11-12

Taysha Gene Therapies, Inc. Annual Net Cash Provided by (Used in) Operating Activities (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 -$81.2M -$8.21M -11.2% Jan 1, 2024 Dec 31, 2024 10-K 2025-02-26
2023 -$73M +$15.4M +17.4% Jan 1, 2023 Dec 31, 2023 10-K 2025-02-26
2022 -$88.4M +$28.7M +24.5% Jan 1, 2022 Dec 31, 2022 10-K 2024-03-19
2021 -$117M -$86.3M -281% Jan 1, 2021 Dec 31, 2021 10-K 2023-03-28
2020 -$30.7M Jan 1, 2020 Dec 31, 2020 10-K 2022-03-31
* An asterisk sign (*) next to the value indicates that the value is likely invalid.